Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment

Pain

Volumn 146, Issue 3, 2009, Pages 270-275

  Walter, Carmen ^a   Lötsch, Jörn ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Meta analysis; Opioid receptors; Pharmacogenetics

Indexed keywords

OPIATE;

ALLELE; ARTICLE; CLINICAL TRIAL; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; META ANALYSIS; MU OPIOID RECEPTOR 1 GENE; PAIN; PHENOTYPE; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

ANALGESICS, OPIOID; DATA INTERPRETATION, STATISTICAL; GENETIC VARIATION; HUMANS; PAIN; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU;

EID: 70350620288     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2009.07.013     Document Type: Article

References (47)

1. Ando Y., Saka H., Ando M., Sawa T., Muro K., Ueoka H., Yokoyama A., Saitoh S., Shimokata K., and Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60 (2000) 6921-6926
2. Barnett J.H., Scoriels L., and Munafo M.R. Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry 64 (2008) 137-144
3. Beyer A., Koch T., Schroder H., Schulz S., and Höllt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 89 (2004) 553-560
4. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., Gong J., Schluger J., Strong J.A., Leal S.M., Tischfield J.A., Kreek M.J., and Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95 (1998) 9608-9613
5. Campa D., Gioia A., Tomei A., Poli P., and Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 83 (2008) 559-566
6. Chou W.Y., Wang C.H., Liu P.H., Liu C.C., Tseng C.C., and Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 105 (2006) 334-337
7. Chou W.Y., Yang L.C., Lu H.F., Ko J.Y., Wang C.H., Lin S.H., Lee T.H., Concejero A., and Hsu C.J. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 50 (2006) 787-792
8. Cohen J. A power primer. Psychol Bull 112 (1992) 155-159
9. Fillingim R.B., Kaplan L., Staud R., Ness T.J., Glover T.L., Campbell C.M., Mogil J.S., and Wallace M.R. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain 6 (2005) 159-167
10. Goetz M.P., Kamal A., and Ames M.M. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 83 (2008) 160-166
11. Goldstein D.B. Common genetic variation and human traits. N Engl J Med 360 (2009) 1696-1698
12. Hardy G.H. Mendelian proportions in a mixed population. Science 28 (1908) 49-50
13. Hayashida M., Nagashima M., Satoh Y., Katoh R., Tagami M., Ide S., Kasai S., Nishizawa D., Ogai Y., Hasegawa J., Komatsu H., Sora I., Fukuda K., Koga H., Hanaoka K., and Ikeda K. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 9 (2008) 1605-1616
14. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
15. Hirota T., Ieiri I., Takane H., Sano H., Kawamoto K., Aono H., Yamasaki A., Takeuchi H., Masada M., Shimizu E., Higuchi S., and Otsubo K. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos 31 (2003) 677-680
16. Huang C.J., Liu H.F., Su N.Y., Hsu Y.W., Yang C.H., Chen C.C., and Tsai P.S. Association between human opioid receptor genes polymorphisms and pressure pain sensitivity in females. Anaesthesia 63 (2008) 1288-1295
17. Huedo-Medina T.B., Sanchez-Meca J., Marin-Martinez F., and Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index?. Psychol Methods 11 (2006) 193-206
18. Huehne K., Leis S., Muenster T., Wehrfritz A., Winter S., Maihofner C., Foertsch T., Croner R., Reis A., Winterpacht A., and Rautenstrauss B. High post surgical opioid requirements in Crohn's disease are not due to a general change in pain sensitivity. Eur J Pain (2009) January 21 [Epub ahead of print]
19. Klepstad P., Rakvag T.T., Kaasa S., Holthe M., Dale O., Borchgrevink P.C., Baar C., Vikan T., Krokan H.E., and Skorpen F. The 118A>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 48 (2004) 1232-1239
20. Kroslak T., Laforge K.S., Gianotti R.J., Ho A., Nielsen D.A., and Kreek M.J. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 103 (2007) 77-87
21. Landau R., Kern C., Columb M.O., Smiley R.M., and Blouin J.L. Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain 139 (2008) 5-14
22. Lötsch J. Basic genetic statistics are necessary in studies of functional associations in anesthesiology. Anesthesiology 107 (2007) 168-169 author reply 169
23. Lötsch J., Flühr K., Neddermayer T., Doehring A., and Geisslinger G. The consequence of concomitantly present functional genetic variants for the identification of functional genotype-phenotype associations in pain. Clin Pharmacol Ther 85 (2009) 25-30
24. Lötsch J., and Geisslinger G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J 6 (2006) 200-210
25. Lötsch J., Skarke C., Grösch S., Darimont J., Schmidt H., and Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the clinical activity of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12 (2002) 3-9
26. Lötsch J., Skarke C., Wieting J., Oertel B.G., Schmidt H., Brockmöller J., and Geisslinger G. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 79 (2006) 72-89
27. Lötsch J., Stuck B., and Hummel T. The human mu-opioid receptor gene polymorphism 118A>G decreases cortical activation in response to specific nociceptive stimulation. Behav Neurosci 120 (2006) 1218-1224
28. Lötsch J., von Hentig N., Freynhagen R., Griessinger N., Zimmermann M., Doehring A., Rohrbacher M., Sittl R., and Geisslinger G. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics 19 (2009) 429-436
29. Lötsch J., Zimmermann M., Darimont J., Marx C., Dudziak R., Skarke C., and Geisslinger G. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?. Anesthesiology 97 (2002) 814-819
30. Milano G., Etienne M.C., Pierrefite V., Barberi-Heyob M., Deporte-Fety R., and Renee N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79 (1999) 627-630
31. Oertel B.G., Kettner M., Scholich K., Renne C., Roskam B., Geisslinger G., Schmidt P.H., and Lötsch J. A common human mu-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem 284 (2009) 6530-6535
32. Oertel B.G., Preibisch C., Wallenhorst T., Hummel T., Geisslinger G., Lanfermann H., and Lötsch J. Differential opioid action on sensory and affective cerebral pain processing. Clin Pharmacol Ther 83 (2008) 577-588
33. Oertel B.G., Schmidt R., Schneider A., Geisslinger G., and Lötsch J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 16 (2006) 625-636
34. Ono T., Muto A., Kaneda T., Arita E., and Yoshida T. Novel linkage disequilbrium of single nucleotide polymorphisms in the transcriptional regulatory region of micro-opioid receptor gene in Japanese population. Biol Pharm Bull 32 (2009) 721-723
35. Orwin R.G. A fail-safe N for effect size in meta-analysis. J Educ Stat 8 (1983) 157-159
36. Reyes-Gibby C.C., Shete S., Rakvag T., Bhat S.V., Skorpen F., Bruera E., Kaasa S., and Klepstad P. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130 (2007) 25-30
37. Romberg R., Olofsen E., Sarton E., den Hartigh J., Taschner P.E., and Dahan A. Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. Anesthesiology 100 (2004) 120-133
38. Romberg R.R., Olofsen E., Bijl H., Taschner P.E., Teppema L.J., Sarton E.Y., van Kleef J.W., and Dahan A. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 102 (2005) 522-530
39. Sia A.T., Lim Y., Lim E.C., Goh R.W., Law H.Y., Landau R., Teo Y.Y., and Tan E.C. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 109 (2008) 520-526
40. Skarke C., Darimont J., Schmidt H., Geisslinger G., and Lötsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 73 (2003) 107-121
41. Skarke C., Jarrar M., Erb K., Schmidt H., Geisslinger G., and Lötsch J. Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther 74 (2003) 303-311
42. Skarke C., Langer M., Jarrar M., Schmidt H., Geisslinger G., and Lötsch J. Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans. Anesthesiology 101 (2004) 1394-1399
43. Twycross R., and Wilcock A. Palliative care formulary. 3rd ed. (2007), Palliative books.com, Oxford p. 269
44. Wang J.B., Johnson P.S., Persico A.M., Hawkins A.L., Griffin C.A., and Uhl G.R. Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett 338 (1994) 217-222
45. Wei L.X., Floreani A., Variola A., El Younis C., and Bergasa N.V. A study of the mu opioid receptor gene polymorphism A118G in patients with primary biliary cirrhosis with and without pruritus. Acta Derm Venereol 88 (2008) 323-326
46. Wendel B., and Hoehe M.R. The human mu opioid receptor gene: 5′ regulatory and intronic sequences. J Mol Med 76 (1998) 525-532
47. Zhang Y., Wang D., Johnson A.D., Papp A.C., and Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280 (2005) 32618-32624